92
VOLUME 11 NUMBER 2 • JUNE 2014
REVIEW
SA JOURNAL OF DIABETES & VASCULAR DISEASE
References
1.
Preis SR, Hwang SJ, Coady S,
et al
. Trends in all-cause and cardiovascular disease
mortality among women and men with and without diabetes mellitus in the
Framingham Heart Study, 1950 to 2005.
Circulation
2009;
119
:1728–1735.
2.
Nishimura R, LaPorte RE, Dorman JS,
et al
. Mortality trends in type 1 diabetes.
The Allegheny County (Pennsylvania) Registry 1965–1999.
Diabetes Care
2001;
24
:823–827. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard
TJ. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh
Epidemiology of Diabetes Complications study cohort.
Diabetes
2012,
61
:2987-
2992.
3.
Schnell O, Standl E: Diabetes and cardiovascular disease. Current status of trials.
Clin Res Cardiol Suppl
2010;
5
:27–34.
4.
Koivisto VA, Stevens LK, Mattock M,
et al.
Cardiovascular disease and its risk
factors in IDDM in Europe, EURODIAB IDDM Complications Study Group.
Diabetes Care
1996;
19
: 689–697.
5.
Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Similarity of the impact
of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects.
Diabetes Care
2008;
31
:714–719.
6.
Standl E, Balletshofer B, Dahl B,
et al.
Predictors of 10-year macrovascular and
overall mortality in patients with NIDDM: the Munich General Practitioner Project.
Diabetologia
1996;
39
:1540–1545.
7.
Shankar A, Klein R, Klein BE, Moss SE. Association between glycosylated
hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes.
Am J Epidemiol
2007;
166
: 393–402.
8.
Morimoto A, Onda Y, Nishimura R,
et al
. Cause-specific mortality trends in a
nationwide population-based cohort of childhood-onset type 1 diabetes in Japan
during 35 years of follow-up: the DERI Mortality Study.
Diabetologia
2013;
56
:
2171–2175.
9.
Constantino MI, Molyneaux L, Limacher-Gisler F,
et al
. Long-Term Complications
and Mortality in Young-Onset Diabetes: Type 2 diabetes is more hazardous and
lethal than type 1 diabetes.
Diabetes Care
2013.
10. Ryden L, Standl E, Bartnik M,
et al
. Guidelines on diabetes, pre-diabetes, and
cardiovascular diseases: executive summary. The Task Force on Diabetes and
Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the
European Association for the Study of Diabetes (EASD).
Eur Heart J
2007;
28
:
88–136.
11. Ceriello A. New insights on oxidative stress and diabetic complications may lead
to a "causal" antioxidant therapy.
Diabetes Care
2003;
26
: 1589–1596.
12. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to
treat?
Diabetes
2005;
54
: 1–7.
13. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular
events.
Diabetes Care
2010;
33
: 1389–1394.
14. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes.
Diab Vasc Dis
Res
2010;
7
: 260–273.
15. Spallone V, Ziegler D, Freeman R,
et al
. Cardiovascular autonomic neuropathy
in diabetes: clinical impact, assessment, diagnosis, and management.
Diabetes
Metab Res Rev
2011. doi:
10
.1002/dmrr.1239.
16. Witte DR, Tesfaye S, Chaturvedi N,
et al
. Risk factors for cardiac autonomic
neuropathy in type 1 diabetes mellitus.
Diabetologia
2005,
48
:164-171.
17. The DCCT Research Group. The effect of intensive diabetes therapy on measures
of autonomic nervous system function in the Diabetes Control and Complications
Trial (DCCT).
Diabetologia
1998;
41
: 416–423.
18. Pop-Busui R, Low PA, Waberski BH,
et al.
Effects of prior intensive insulin therapy
on cardiac autonomic nervous system function in type 1 diabetes mellitus: the
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions
and Complications study (DCCT/EDIC).
Circulation
2009;
119
: 2886–2893.
19. Astrup AS, Tarnow L, Rossing P,
et al
. Cardiac autonomic neuropathy predicts
cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic
nephropathy.
Diabetes Care
2006;
29
: 334–339.
20. Ayad F, Belhadj M, Paries J, Attali JR, Valensi P: Association between cardiac
autonomic neuropathy and hypertension and its potential influence on diabetic
complications.
Diabet Med
2010;
27
:804–811.
21. Prince CT, Secrest AM, Mackey RH,
et al
. Cardiovascular autonomic neuropathy,
HDL cholesterol, and smoking correlate with arterial stiffness markers determined
18 years later in type 1 diabetes.
Diabetes Care
2010;
33
: 652–657.
22. Standl E, Schnell O. A new look at the heart in diabetes mellitus: from ailing to
failing.
Diabetologia
2000;
43
: 1455–1469.
23. Schnell O. Cardiac sympathetic innervation and blood flow regulation of the
diabetic heart.
Diabetes Metab Res Rev
2001;
17
: 243–245.
24. Schnell O, Kirsch CM, Stemplinger J, Haslbeck M, Standl E. Scintigraphic evidence
for cardiac sympathetic dysinnervation in long-term IDDM patients with and
without ECG-based autonomic neuropathy.
Diabetologia
1995;
38
: 1345–1352
25. Hattori N, Tamaki N, Hayashi T,
et al.
Regional abnormality of iodine-123-MIBG in
diabetic hearts.
J Nucl Med
1996;
37
: 1985–1990.
26. SchnellO,MuhrD,WeissM,
etal.
Reducedmyocardial123I-metaiodobenzylguanidine
uptake in newly diagnosed IDDM patients.
Diabetes
1996;
45
: 801–805.
27. Munch G, Ziegler S, Nguyen N,
et al
. Scintigraphic evaluation of cardiac autonomic
innervation.
J Nucl Cardiol
1996;
3
: 265–277.
28. Schnell O, Muhr D, Dresel S,
et al.
Partial restoration of scintigraphically assessed
cardiac sympathetic denervation in newly diagnosed patients with insulin-
dependent (type 1) diabetes mellitus at one-year follow-up.
Diabet Med
1997;
14
: 57–62.
29. Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism in
diabetes mellitus.
Am J Cardiol
1997;
80
: 94A–101A.
30. Stevens MJ, Dayanikli F, Raffel DM,
et al.
Scintigraphic assessment of regionalized
defects in myocardial sympathetic innervation and blood flow regulation in
diabetic patients with autonomic neuropathy.
J Am Coll Cardiol
1998;
31
: 1575–
1584.
31. Vom-Dahl J, Herman WH, Hicks RJ,
et al
. Myocardial glucose uptake in patients
with insulin-dependent diabetes mellitus assessed quantitatively by dynamic
positron emission tomography.
Circulation
1993;
88
: 395–404.
32. Hattori N, Tamaki N, Kudoh T,
et al
. Abnormality of myocardial oxidative
metabolism in noninsulin-dependent diabetes mellitus.
J Nucl Med
1998;
39
:
1835–1840.
33. Pop-Busui R. What do we know and we do not know about cardiovascular
autonomic neuropathy in diabetes.
J Cardiovasc Transl Res
2012;
5
: 463–478.
34. Pop-Busui R, Kirkwood I, Schmid H,
et al.
: Sympathetic dysfunction in type 1
diabetes: association with impaired myocardial blood flow reserve and diastolic
dysfunction.
J Am Coll Cardiol
2004;
44
: 2368–2374.
35. Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present, and
future.
Diabetes
1995;
44
: 1355–1361.
36. Allman KC, Stevens MJ, Wieland DM,
et al
. Noninvasive assessment of cardiac
diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission
tomography.
J Am Coll Cardiol
1993;
22
: 1425–1432.
37. Stevens MJ, Raffel DM, Allman KC,
et al
. Cardiac sympathetic dysinnervation
in diabetes: implications for enhanced cardiovascular risk.
Circulation
1998;
98
:
961–968.
38. Schnell O, Muhr D, Dresel S,
et al.
Autoantibodies against sympathetic ganglia
and evidence of cardiac sympathetic dysinnervation in newly diagnosed and long-
term IDDM patients.
Diabetologia
1996;
39
: 970–975.
39. Muhr D, Mollenhauer U, Ziegler AG,
et al.
Autoantibodies to sympathetic ganglia,
GAD, or tyrosine phosphatase in long-term IDDM with and without ECG-based
cardiac autonomic neuropathy.
Diabetes Care
1997;
20
: 1009–1012.
40. Muhr-Becker D, Ziegler AG, Druschky A,
et al
. Evidence for specific autoimmunity
against sympathetic and parasympathetic nervous tissues in Type 1 diabetes
mellitus and the relation to cardiac autonomic dysfunction.
Diabet Med
1998;
15
: 467–472.
41. Ejskjaer N, Arif S, Dodds W,
et al.
Prevalence of autoantibodies to autonomic nervous
tissue structures in Type 1 diabetes mellitus.
Diabet Med
1999;
16
: 544–549.
42. Rabinowe SL, Brown FM, Watts M, Kadrofske MM, Vinik AI. Anti-sympathetic
ganglia antibodies and postural blood pressure in IDDM subjects of varying duration
and patients at high risk of developing IDDM.
Diabetes Care
1989;
12
: 1–6.
43. Sundkvist G, Lind P, Bergstrom B, Lilja B, Rabinowe SL. Autonomic nerve
antibodies and autonomic nerve function in type 1 and type 2 diabetic patients.
J Intern Med
1991;
229
: 505–510.
44. Zanone MM, Peakman M, Purewal T, Watkins PJ, Vergani D. Autoantibodies to
nervous tissue structures are associated with autonomic neuropathy in type 1
(insulin-dependent) diabetes mellitus.
Diabetologia
1993;
36
: 564–569.
45. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks.
Diabetes Care
2011;
34(
Suppl 2): S132–S137.
46. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an
aggravating factor?
Diabetes Metab Res Rev
2008;
24
: 353–363.
47. Sommerfield AJ, Wilkinson IB, Webb DJ, Frier BM. Vessel wall stiffness in type
1 diabetes and the central hemodynamic effects of acute hypoglycemia.
Am J
Physiol Endocrinol Metab
2007;
293
: E1274–E1279.
48. Robinson RT, Harris ND, Ireland RH,
et al
. Mechanisms of abnormal cardiac
repolarization during insulin-induced hypoglycemia.
Diabetes
2003;
52
: 1469–
1474.
49. Koivikko ML, Karsikas M, Salmela PI,
et al.
Effects of controlled hypoglycaemia
on cardiac repolarisation in patients with type 1 diabetes. Diabetologia 2008;
51
:
426–435.
50. Tattersall RB, Gill GV: Unexplained deaths of type 1 diabetic patients.
Diabet Med
1991;
8
: 49–58.
51. Campbell I. Dead in bed syndrome: a new manifestation of nocturnal
hypoglycaemia?
Diabet Med
1991;
8
: 3–4.
